| Record 6462 View: Standard | Glossary HistCite Guide |
|
Author(s): Meunier JC
Title: Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor
Source: EUROPEAN JOURNAL OF PHARMACOLOGY 340 (1): 1-15
Date: 1997 DEC 4
Document Type: Journal : Review
DOI:
Language: English
Comment:
Address: Inst Pharmacol & Biol Struct, Unite Neuropharmacol Mol, CNRS, UPR 9062, F-31077 Toulouse 4, France.
Reprint: Meunier, JC, Inst Pharmacol & Biol Struct, Unite Neuropharmacol Mol,
CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse 4, France. E-mail: jcm@ipbs.fr
Abstract: Homology cloning and, more recently, the sequencing of whole genomes, have identified many open reading frames encoding proteins of unknown function, in particular putative G protein-coupled membrane receptors. Identification of orphan receptors in this way has marked the advent of 'reverse pharmacology' to identify the corresponding physiological ligands. This approach has led to the discovery of the ORL1 (Opioid Receptor-Like 1) receptor, and of its natural ligand, nociceptin/orphanin FQ (noc/oFQ), the basic components of a new peptide-based signalling pathway in the nervous sytem. Based on genetic criteria, the ORL1 and opioid receptors belong to the same family, as do noc/oFQ and opioid peptides. The marked structural analogy between the ORL1 and opioid receptors, especially the K-opioid receptor, and the noc/oFQ and opioid peptides, particularly dynorphin A, is not reflected anatomically since noc/oFQ and opioid peptides appear to be located in separate neuronal circuits. Noc/oFQ triggers the same G protein-mediated signalling pathways as do opioids, however, to produce pharmacological effects that sometimes differ from, and even oppose, those of opioids. Noc/oFQ stimulates an outward K+ current and/or inhibits voltage-gated Ca2+ channels, thereby reducing synaptic efficacy, i.e. neuronal activity. In the rat, noc/oFQ is endowed with supraspinal pronociceptive/anti-opioid properties (it suppresses opioid-mediated analgesia), while convergent electrophysiological and behavioural data indicate that the peptide is a spinal analgesic. Noc/oFQ has not yet been found to precipitate withdrawal in morphine-tolerant rats. Nor does it elicit motivational effects, suggesting it lacks abuse liability. Also, by acting supraspinally, noc/oFQ impairs motor performance, suppresses spatial learning, induces feeding, and regulates basal and stress-induced release of pituitary hormones. Noc/oFQ is also active when administered intravenously, exhibiting potent smooth muscle relaxant, diuretic, and antinatriuretic properties. Last but not least, noc/oFQ appears to regulate stimulated immune function, and to be involved in neuronal differentiation. The discovery of noc/oFQ, a neuropeptide with multiple functions, will certainly improve our knowledge of brain physiology, and may find therapeutic applications, for example in the management of pain or hyponatremic and water-retaining diseases. However, given the wide distribution of noc/oFQ and its receptor, the pharmacological profile of noc/oFQ is likely to be incomplete, and other as yet unknown functions of the peptide remain to be discovered. Most helpful in this respect will be the identification of new ligands of the ORL1 receptor, particularly antagonists. If research on noc/oFQ carries on unabated at the present pace, potentially clinically interesting new compounds could become available in the not too distant future. (C) 1997 Elsevier Science B.V.
Cited References: ANTON B, 1996, J COMP NEUROL, V368, P229 BERZETEIGURSKE IP, 1996, EUR J PHARMACOL, V302, PR1 BLUETPAJOT MT, 1997, 3 COLL SOC NEUR BORD, P122 BUNZOW JR, 1994, FEBS LETT, V347, P284 BUTOUR JL, 1997, EUR J PHARMACOL, V321, P97 CALO G, 1996, EUR J PHARMACOL, V311, PR3 CHAMPION HC, 1997, LIFE SCI, V60, PL241 CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543 CHEN Y, 1994, FEBS LETT, V347, P279 CHENG J, 1995, J NEUROCHEM, V65, P170 CONNOR M, 1996, BRIT J PHARMACOL, V118, P205 CONNOR M, 1996, BRIT J PHARMACOL, V119, P1614 DAWSONBASOA M, 1997, BRAIN RES, V750, P48 DEVINE DP, 1996, BRAIN RES, V727, P225 DEVINE DP, 1996, NEUROCHEM RES, V21, P1387 DHAWAN BN, 1996, PHARMACOL REV, V48, P567 DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185 DOOLEY CT, 1996, 27 INT NARC RES C LO, P78 DOOLEY CT, 1996, LIFE SCI, V59, P23 FABER ESL, 1996, BRIT J PHARMACOL, V119, P189 FLORIN S, 1996, EUR J PHARMACOL, V317, P9 FRANCES B, 1985, EUR J PHARMACOL, V117, P223 FUKUDA K, 1994, FEBS LETT, V343, P42 GINTZLER AR, 1997, EUR J PHARMACOL, V325, P29 GIULIANI S, 1996, BRIT J PHARMACOL, V118, P1567 GRISEL JE, 1996, NEUROREPORT, V7, P2125 GUMUSEL B, 1997, LIFE SCI, V60, P141 HALFORD WP, 1995, J NEUROIMMUNOL, V59, P91 HAO JX, 1997, NEUROSCI LETT, V223, P49 HOUTANI T, 1996, BIOCHEM BIOPH RES CO, V219, P714 IKEDA K, 1997, MOL BRAIN RES, V45, P117 JULIUS D, 1995, NATURE, V377, P476 KAPUSTA DR, 1997, LIFE SCI, V60, P15 KAVALIERS M, 1996, PEPTIDES, V17, P763 KIEFFER BL, 1995, CELL MOL NEUROBIOL, V15, P615 KIEFFER BL, 1997, PAIN HDB EXPT PHARM, V130, P281 KING MA, 1997, NEUROSCI LETT, V223, P113 KNOFLACH F, 1996, J NEUROSCI, V16, P6657 KOBAYASHI T, 1997, BRIT J PHARMACOL, V120, P986 KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177 LACHOWICZ JE, 1995, J NEUROCHEM, V64, P34 LEMOAL M, 1991, PHYSIOL REV, V71, P155 LIBERT F, 1989, SCIENCE, V244, P569 MA L, 1997, FEBS LETT, V403, P91 MATHIS JP, 1997, BIOCHEM BIOPH RES CO, V230, P462 MATTHES H, 1996, MOL PHARMACOL, V50, P447 MENG F, 1996, J BIOL CHEM, V271, P32016 MEUNIER JC, 1992, THERAPIE, V47, P495 MEUNIER JC, 1995, NATURE, V377, P532 MILLS A, 1993, TRENDS PHARMACOL SCI, V14, P394 MOGIL JS, 1996, NEUROSCI LETT, V214, P131 MOGIL JS, 1996, NEUROSCIENCE, V75, P333 MOLLEREAU C, 1994, FEBS LETT, V341, P33 MOLLEREAU C, 1996, 27 INT NARC RES C LO, P75 MOLLEREAU C, 1996, FEBS LETT, V395, P17 MOLLEREAU C, 1996, P NATL ACAD SCI USA, V93, P8666 MONTIEL JL, 1997, J NEUROCHEM, V68, P354 MORLEY JE, 1983, NEUROSCI BIOBEHAV R, V7, P281 MURPHY NP, 1996, NEUROSCIENCE, V75, P1 NEAL MJ, 1997, BRIT J PHARMACOL, V120, P1399 NICOL B, 1996, BRIT J PHARMACOL, V119, P1081 NISHI M, 1994, BIOCHEM BIOPH RES CO, V205, P1353 NISHI M, 1997, EMBO J, V16, P1858 NOBLE F, 1997, FEBS LETT, V401, P227 NOTHACKER HP, 1996, P NATL ACAD SCI USA, V93, P8677 OKUDAASHITAKA E, 1996, MOL BRAIN RES, V43, P96 PAN YX, 1996, BIOCHEM J 1, V315, P11 PANULA P, 1996, PROG NEUROBIOL, V48, P461 PARMENTIER M, 1995, M S-MED SCI, V11, P222 PETSKO GA, 1996, NATURE S, V384, P7 POMONIS JD, 1996, NEUROREPORT, V8, P369 REINSCHEID RK, 1995, SCIENCE, V270, P792 REINSCHEID RK, 1996, J BIOL CHEM, V271, P14163 REISINE T, 1993, TRENDS NEUROSCI, V16, P506 RIEDL M, 1996, NEUROREPORT, V7, P1369 ROSSI GC, 1996, EUR J PHARMACOL, V311, PR7 ROWE PM, 1996, LANCET, V347, P606 SAITO Y, 1995, BIOCHEM BIOPH RES CO, V217, P539 SAITO Y, 1996, J BIOL CHEM, V271, P15615 SALVADORI S, 1997, BIOCHEM BIOPH RES CO, V233, P640 SANDIN J, 1997, EUR J NEUROSCI, V9, P194 SATOH M, 1995, PHARMACOL THERAPEUT, V68, P343 SCHULIGOI R, 1997, NEUROSCI LETT, V224, P136 SCHULZ S, 1996, NEUROREPORT, V7, P3021 SCHWARTZ JC, 1993, MED SCI, V9, P9 SCHWYZER R, 1977, ANN NY ACAD SCI, V297, P3 SHIMOHIGASHI Y, 1996, J BIOL CHEM, V271, P23642 SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242 SIM LJ, 1996, NEUROREPORT, V7, P729 SIMONDS WF, 1988, ENDOCR REV, V9, P200 SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046 STANFA LC, 1996, BRIT J PHARMACOL, V118, P1875 STRATFORD TR, 1997, NEUROREPORT, V8, P423 TIAN JH, 1997, BRIT J PHARMACOL, V120, P676 TIAN JH, 1997, NEUROREPORT, V8, P497 VAUGHAN CW, 1996, BRIT J PHARMACOL, V117, P1609 VAUGHAN CW, 1997, J NEUROSCI, V17, P996 WALKER JM, 1982, SCIENCE, V218, P1136 WANG JB, 1994, FEBS LETT, V348, P75 WANG XM, 1996, J NEUROPHYSIOL, V76, P3568 WICK MJ, 1994, MOL BRAIN RES, V27, P37 WICK MJ, 1995, MOL BRAIN RES, V32, P342 XU XJ, 1996, NEUROREPORT, V7, P2092 YAMAMOTO T, 1997, BRAIN RES, V754, P329 YAMAMOTO T, 1997, NEUROSCI LETT, V224, P107 YU J, 1996, PEPTIDES, V17, P873 YU TP, 1997, HIPPOCAMPUS, V7, P88 ZHANG SW, 1995, J BIOL CHEM, V270, P22772 |